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We have employed a short-term transfection assay system in which we monitored the transient expression of the chloram- 
phenicol acetyltransferase (CAT) gene linked to the promoter region of the normal and mutant T24 H-rasl gene or the 
human s-globin gene in Chinese hamster lung (CHL) cells or cells derived from them which carry and express one or 
the other of the polyoma virus early genes. Our findings can be summarized as follows: (i) The mutant T24 H-rusl pro- 
moter region behaves as a stronger promoter than the H-rasl gene in all these types of cells as well as in rat 208F fibro- 
blast cells. (ii) In CHL cells expressing the polyoma large T antigen the normal and mutant T24 Ha-rsl promoters are 
not trans-activated in these cells and only a 2.5fold activation of the s-globin promoter is observed. (iii) In cells expressing 
the polyoma middle T antigen both the normal and mutant H-rasl are tram-activated whereas transcription from the 
s-globin promoter is not affected when compared to the normal CHL cells. (iv) In cells expressing the polyoma small 
T antigen the normal and mutant H-ru.sl as well as the s-globin promoters are trans-activated. We suggest from these 
data that a tissue-specific element exists in the promoter region of the H-rarl gene and that the polyoma middle and 
small T antigens trigger the expression of proteins that trans-activate these promoters. 
Trans-activation; H-ras oncogene; Polyoma oncogene 
1. INTRODUCTION 
The analysis of transcriptional control of the ras 
genes is of special interest, since members of the 
rus family are often activated in human tumors by 
point mutations [1,2], elevated expression of ras 
RNA transcripts [3,4] and ras p21 protein [5,6]. 
The demonstration that when linked to a strong 
transcriptional enhancer the H-rusl gene can im- 
mortalize [7] or tumorigenically convert [8] cells in 
vitro suggests that transcriptional control plays an 
important role in the tumorigenesis induced by the 
H-rasl gene. Recently, transcription regulatory se- 
quences have been found at both the 5 ’ [9-121 and 
3 ’ [13] ends of this gene. Although the ras gene is 
constitutively expressed in many cells it is of in- 
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terest that some normal tissues express MS genes at 
higher levels [ 141. Evidence has been obtained to 
suggest he presence of a transcriptional enhancer 
element at the promoter region of the H-rasl gene 
[lo]. Such elements are often found to be trans- 
activated [ 151, trans-repressed [ 161 or to be tissue- 
specific [ 171. 
There is accumulating evidence to suggest that 
transcriptional activation by trans-acting 
mechanisms may be important in oncogenesis 
[ 18-201. A number of viral oncogenes, i.e. 
adenovirus ElA [21], SV40 T antigen [22] and 
human T lymphotropic viruses [23], encode pro- 
teins with the ability to stimulate transcription. A 
number of cellular oncogene products share some 
common properties with these viral gene products, 
i.e. they are located in the nucleus and it has been 
suggested that both these types of proteins may 
regulate transcription of a set of genes important 
in growth control. 
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Here, we have examined whether expression 
from the normal and T24 mutant H-rasl pro- 
moters is affected in cells expressing one or the 
other of the polyoma virus early genes and have in- 
vestigated the potency of the two ras gene pro- 
moters in hamster and rat cells. 
2. MATERIALS AND METHODS 
2.1. Cells and plasmids 
The Chinese hamster lung (CHL) late passage cells and the 
geneticin-resistant CHL transfectant cell clones FH06LTl-1, 
FHO6MTl-1 and FHO6STl-1 have been described [24]. Clones 
FHO6LTl-1, FH06MTl-1 and FHO6STl-1 were obtained after 
transfection of early passage CHL cells with recombinant 
plasmids pHO6LT1, pHO6MTl and pHO6STl carrying the 
polyoma large, middle and small T antigen gene, respectively. 
These plasmids also carry the aminoglycoside phosphotrans- 
ferase aph gene which renders recipient cells resistant to 
geneticin. FHO6LTl-1, FH06MTl-1 and FHO6STl-1 cells ex- 
press the exogenous polyoma genes ([25]; unpublished). The rat 
fibroblast (208F) cells have previously been described [lo]. 
Plasmids pCATl22A and pCATl23A carry the normal or 
T24 mutant H-rasl gene promoter egion linked to the chloram- 
phenicol acetyltransferase (CAT) gene and have been described 
in [lo]. Plasmid pB30 carries the human e-globin gene promoter 
linked to the CAT gene and has also been described [13]. 
2.2. Transfection procedure and CAT assay 
DNA transfections into recipient cells were performed using 
a modification [26] of the calcium phosphate technique [27]. 
Cells were harvested and assayed for CAT activity at 48 h after 
transfection as in [10,28]. 
3. RESULTS 
The ability of the normal and T24 mutant Ha- 
rasl promoters as well as the human e-globin pro- 
moter to express the CAT gene in CHL cells and 
in CHL cells expressing one or the other of the 
polyoma virus early genes was tested by transfec- 
ting purified plasmid DNA into these cells and 
determining the resulting CAT activity 48 h after 
transfection. The results are shown in fig.1 and 
tables l-3. The following points can be drawn 
from these data. (i) The T24 mutant H-rasl pro- 
moter behaves as a stronger promoter 
Fig. 1. Chromatograms for typical CAT assays upon 
transfection of CHL cells with CAT recombinants. Experiment 
using the CHL and FHO6LTl-1 (a), FHO6MTl-1 (b) and 
FH06STl-1 (c) as recipient cells. 
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Table 1 
Relative values of CAT activity in Chinese hamster cells after transfection with 
CAT recombinant plasmids 
Cells” Recombinant Exogenous 
polyoma virus DNA’ 
plasmidb 
CAT CAT activity 
promoter (average + SD)d 
CHL - pLW4 HSV 254 + 12 
CHL _ salmon _ 0.7 * 0.3 
CHL _ pCATl22A H-rasl 1.0 
FHO6LTl-1 pH06LTl pCATl22A H-ras 1 1.4 + 0.3 
CHL - pCATl23A T24 H-rasl 8.6 k 0.6 
FHO6LTl-1 pH06LTl pCATl23A T24 H-rasl 10 Ik 1.3 
CHL _ pB30 e-globin 1.2 * 0.2 
FH06LTl-1 pH06KT 1 pB30 l -globin 2.5 f 0.4 
a CHL, late passage of primary CHL cells; FHO6LTl-1, cell clone obtained 
after transfection of 3rd passage CHL cells with recombinant plasmid 
pH06LT1, carrying the polyoma large T antigen gene and the uph gene for 
geneticin resistance selection, as in [23] 
b~c See section 2 for plasmid derivation 
d Relative values of CAT activity of each plasmid vs that obtained with 
pCATl22A. The value for CAT activity after transfection of 4Opg 
pCATl22A per 5 x lo6 Chinese hamster cells was 3.4 x 10v4 pmol 
acetylated chloramphenicol/pg protein per h incubation. Average + 
standard deviation from 3 experiments hown 
(8.4-8.6-fold higher) when compared to the nor- 
mal H-rasl promoter in these cells. This finding 
demonstrates a tissue-specific activity, since in our 
previous study with rat 208F fibroblast cells no 
significant difference was observed between the 
promoters [lo]. (ii) Whereas the human e-globin 
promoter is trans-activated by the polyoma large T 
antigen (from 1.2- to 2.Sfold) neither normal nor 
mutant H-rus promoters are significantly affected 
in this respect (fig.la, table 1). (iii) In CHL cells 
expressing the polyoma middle T antigen both the 
normal and mutant H-rasl promoters are trans- 
activated. The CAT values rise from l.O- to 
2.4-fold and from 4.6- to 17-fold, respectively. 
Transcription from the e-globin promoter is not af- 
fected, since CAT values remain almost unchanged 
(1.2-l. 1) (fig. 1 b and table 2). (iv) In CHL cells ex- 
pressing the polyoma small T antigen the normal 
and mutant H-rasl as well as the e-globin pro- 
moters are all trans-activated. The CAT values rise 
Table 2 
Relative values of CAT activity in Chinese hamster cells after transfection with 
CAT recombinant plasmids 
Cells” Recombinant Exogenous 
polyoma virus DNAC 
plasmidb 
CAT CAT activity 
promoter (average f SD)d 
CHL - pLW4 HSV 245 f 14 
CHL _ salmon _ 0.8 f 0.3 
CHL _ pCATl22A H-rasl 1.0 
FHO6MTl-1 pHO6MTl pCATl22A H-rasl 2.4 f 0.3 
CHL - pCATl23A T24 H-rasl 4.6 f. 0.4 
FHO6MTl-1 pH06MTl pCATl23A T24 H-rasl 17 * 1.5 
CHL _ pB30 f-globin 1.2 * 0.2 
FHO6MTl-1 pHO6MTl pB30 f-globin 1.1 + 0.2 
a-d See table 1; also FHO6MTl-1 carries the polyoma middle T gene 
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Table 3 
Relative values of CAT activity in Chinese hamster cells after transfection with 
CAT recombinant plasmids 
May 1988 
CeW Recombinant Exogenous 
polyoma virus DNA’ 
plasmidb 
CAT CAT activity 
promoter (average f SD)d 
CHL 
CHL 
CHL 
FHO6STl-1 
CHL 
FHO6STl-1 
CHL 
FHO6STl-1 
_ pLW4 HSV 253 f 14 
_ salmon - 0.7 f 0.3 
- pCAT122A H-rasl 1.0 
pHO6STl pCAT122A H-rasl 8.6 f 0.7 
- pCAT123A T24 H-rasl 8.4 + 0.3 
pHO6STl pCAT123A T24 H-rasl 20 * 1.7 
- pB30 e-globin 1.1 f 0.2 
pHO6STl pB30 l -globin 5.5 f 0.4 
a-d See table 1; also FH06STl-1 carries the polyoma small T gene . 
from 1 .O to 8.6 and from 8.4 to 20 for the normal 
and T24 Ha-rasl promoter respectively, and from 
1.1 to 5.5 for the e-globin promoter. 
In a previous study [lo] we found no essential 
difference in potency of the normal and T24 H- 
rasl promoters by assaying the CAT activities of 
plasmids pCAT122A and pCAT123A in rat 208F 
fibroblasts. It was therefore of interest o compare 
our results on CHL cells simultaneously to those in 
208F cells. The precise amount of each exogenous 
DNA in each transfection experiment was checked 
Table 4 
Relative values of CAT activity in CHL and rat (208F) cells 
after transfection with CAT recombinant plasmids 
Cell Exogenous CAT CAT activity 
line” DNAb promoter (average + SD)C 
208F pLW4 HSV 69 f 3.0 
CHL pLW4 HSV 56 f 2.8 
208F salmon - 0.4 f 0.1 
CHL salmon _ 0.2 f 0.1 
208F pCAT122A H-rasl 1.2 + 0.1 
CHL pCAT122A H-rasl 1.0 
208F pCAT123A T24 H-rasl 5.0 + 0.4 
CHL pCAT123A T24 H-rasl 4.2 + 0.5 
a See table 1 
b See section 2 
’ Relative values of CAT activity of each plasmid compared to 
that obtained with pCAT122A in CHL cells. The value for 
CAT activity after transfection of 40 pg pCAT122A per 5 x 
lo6 Chinese hamster cells was 8.3 x 10m4 pmol acetylated/pg 
protein per h incubation. Average + standard deviation from 
3 experiments hown 
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by agarose gel electrophoresis in parallel with stan- 
dard plasmid DNA. The results from three in- 
dependent experiments are listed in table 4, a 
representative chromatogram being depicted in 
fig.2. Although our present results confirm the 
presence of promoter activities in the normal and 
mutant T24 ras 0.8 kb DNA fragments they also 
show that the mutant T24 when compared to nor- 
mal H-rasl promoter is more potent in inducing 
CAT activity in both CHL (4.2-fold) and 208F 
(5.0-fold) cells. The latter finding represents a 
discrepancy between these results and our previous ’ 
data [lo] and is not understood at present. 
Fig.2. Chromatograms for typical CAT assays upon 
transfection of Chinese hamster lung (CHL) in rat fibroblast 
(208F) cells with CAT recombinants. 
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4. DISCUSSION 
We have employed expression vectors in which 
transcription of the CAT gene is under the control 
of the human normal or T24 mutant H-rusl gene 
or the human c-globin gene. We have transfected 
these plasmids into cells which express the 
polyoma virus large, middle or small T antigen 
genes. Our transient assay experiments how that 
the middle and small T antigen genes exert a 
stimulatory effect on the two ‘H-rasl promoters 
and the large T and small T antigen gene on the E- 
globin promoter. The question which arises con- 
cerns the mechanism of middle and small T antigen 
action on the ras promoters. The proteins could act 
directly, by binding to DNA sequences, to 
facilitate specific transcription initiation. Alter- 
natively, the proteins might act indirectly by modi- 
fying some component of the transcriptional 
machinery and thereby allow increased transcrip- 
tion from the H-r@ promoters. There is as yet no 
direct evidence to choose between these two 
possibilities. It would also be of interest to ascer- 
tain whether transcription of the endogenous H- 
rm gene is altered in the polyoma transfectant cell 
lines. 
An unexpected but potentially important finding 
in our studies was the demonstration that the mu- 
tant T24 H-rasl promoter/enhancer region is more 
active than the corresponding 0.8 kb SstI DNA 
fragment of the normal H-rasl gene. A possible 
structural basis for this tissue-specific difference 
between normal and mutant H-ras promoters is a 
6 bp deletion in the mutant T24 promoter relative 
to the normal H-rusl gene which is shown in fig.3. 
It is of interest that this sequence is one of several 
5 ’ H-rasl sites homologous to the consensus se- 
quence for binding of the Spl transcription factor 
T24 H-rasl 
promoter deletion 
5’W44<3 
I I I I , I I I I 1 I I I , I I I 
Sp 1 binding G(&ic; j 
site I I 0 I I # I, I@I II I 
‘E’ sequence of cn66r& 
IgG Ii chain 
Fig.3. Comparison of the sequence deleted from the promoter 
of the T24 H-rasl gene, the Spl-binding sequence and the ‘E’ 
tissue-specific sequence of the IgG H chain gene. 
[29,30]. Some resemblance is also seen to the 
tissue-specific element ‘E’ present in the IgG H 
chain enhancer [3 1,321. 
Further studies should address the importance 
of these transcriptional effects for the role of rus 
gene expression in initiation and progression of 
malignant transformation. 
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